Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer

The treatment of lung cancer is one of the major challenges in the field of oncology. According to statistics from the National Cancer Center of China in 2015, lung cancer has the highest incidence and mortality, with 733,300 new cases and 610,200 deaths across the country (1). About 85% of lung cancers are non-small cell lung cancer (NSCLC), of which 30% to 40% are considered resectable tumors, including most stage I-II and a small portion of stage IIIA tumors (2). Very early-stage NSCLC (IA) can be cured by surgery. However, more than 50% of NSCLC patients who undergo surgical treatment will relapse or metastasize within 5 years. Even if there is no lymph node metastasis and the primary

Automated summary

The treatment of lung cancer is a major challenge due to its high incidence and mortality rates. Most cases are non-small cell lung cancer, with a portion being operable. Despite surgical treatment, over 50% of patients experience relapse or metastasis within 5 years.